Hovilpri (Pritelivir): What the New FDA-Approved Herpes Drug Means for You

The Short Version

On Friday, October 9, 2026, the U.S. Food and Drug Administration approved Hovilpri (pritelivir), a tablet for herpes simplex virus (HSV) sores that have not healed with the standard antiviral medicines. It was developed by the German company AiCuris, which Japan's Asahi Kasei acquired in April 2026.

The company calls it the first FDA-approved treatment for this kind of hard-to-treat herpes with a new mechanism of action in nearly 30 years. That is genuinely big news, and it is why the approval made headlines.

Here is the most important part, though: Hovilpri is approved for a narrow group of people, adults with weakened immune systems whose herpes sores did not respond to acyclovir, valacyclovir or famciclovir. It is not a cure, and it does not change the standard treatment for the vast majority of people living with HSV-1 or HSV-2. The company expects it to be available in the United States before the end of 2026.

What Pritelivir Is and How It Works

The antivirals most people with herpes know, acyclovir, valacyclovir and famciclovir, all belong to the same family. They need an enzyme made by the virus itself, called thymidine kinase, to switch them on inside infected cells. When the virus changes that enzyme, it can become resistant to the whole family at once. The CDC notes that every acyclovir-resistant strain is also resistant to valacyclovir, and that most are resistant to famciclovir.

Pritelivir works differently. It is a helicase-primase inhibitor: it blocks the proteins the virus uses to unwind and copy its DNA, and it does not need the viral enzyme to be activated. That is why it can work against herpes that no longer responds to the acyclovir family. It is active against both HSV-1 and HSV-2.

Hovilpri comes as a 100 mg tablet. In the approved regimen, patients take a 400 mg dose on the first day, then 100 mg once a day for up to 28 days, which can be extended to 42 days.

Who It Is Approved For

The official indication is the treatment of mucocutaneous lesions (sores on the skin or the moist linings of the body) caused by HSV that are refractory, with or without documented resistance, to acyclovir, valacyclovir or famciclovir, in immunocompromised adults.

In plain language: adults whose immune systems are weakened and whose herpes sores keep going despite the usual antivirals. According to the company, that group includes people who have had a stem cell or organ transplant, people living with HIV, and people with cancer or with autoimmune and inflammatory conditions.

It is a small group. Asahi Kasei estimates the drug could serve about 15,000 patients in the United States. For comparison, the World Health Organization estimates that hundreds of millions of people worldwide live with genital herpes alone.

What the Trial Showed

The approval rests on part C of PRIOH-1, a Phase 3, randomized, open-label trial in 101 immunocompromised adults whose herpes sores had not responded to standard treatment. Pritelivir was compared with the treatments doctors use for these cases today, chosen by each investigator: intravenous foscarnet, intravenous or topical cidofovir, or topical imiquimod.

By day 28, all herpes sores had healed in 63% of people taking pritelivir, compared with 34% of people on the comparison treatments. By day 42, the response rate was 82% versus 42%.

Pritelivir was also easier to tolerate. Adverse reactions occurred in 22% of people taking pritelivir versus 54% on the comparison treatments, and only 2% stopped treatment because of side effects, versus 20%. The most common side effect was headache (6% versus 4%).

There is one practical caution. Medicines that reduce stomach acid, such as proton pump inhibitors, H2 blockers and antacids, can lower how much pritelivir the body absorbs, so some must be avoided and others spaced apart. Pritelivir can also raise the levels of certain other drugs. That is a conversation for your doctor and pharmacist.

For the people it is approved for, the change is real. The CDC treatment guidelines name intravenous foscarnet as the treatment of choice for acyclovir-resistant genital herpes. Pritelivir is a tablet instead of an IV drip.

Does This Change Anything If You Have HSV?

For most people with herpes, not directly. Resistance to acyclovir is rare in people with healthy immune systems. A large review in Clinical Microbiology Reviews found it in about 0.3% of herpes samples from people with healthy immune systems, compared with typically 4% to 7% in people with weakened immune systems.

That means valacyclovir, acyclovir and famciclovir remain the standard treatment, whether you take them during outbreaks or every day as suppressive therapy. The CDC considers the three equally effective for treating outbreaks, and all three are available as inexpensive generics. If your current treatment works for you, there is no reason to change it.

Hovilpri is not approved for routine genital or oral herpes in people with healthy immune systems. If you have frequent or severe outbreaks, talk to your doctor about your current plan rather than asking for the new drug.

If you are immunocompromised and a herpes sore is not healing on standard antivirals, raise it with your care team now. Testing the virus for resistance and getting specialist advice are part of the standard approach, and Hovilpri may become one of the options.

Why It Still Matters for Everyone With HSV

Even if you never take it, this approval matters. It is the first new way of attacking herpes to reach FDA approval in decades, and it shows that drugs in this class can make it all the way through.

Pritelivir has also been studied in people with healthy immune systems. In a Phase 2 trial published in JAMA in 2016, adults with recurrent genital HSV-2 took pritelivir and valacyclovir for 28 days each. Herpes was detected in 2.4% of genital swabs during pritelivir treatment versus 5.3% during valacyclovir, and genital sores appeared on 1.9% of days versus 3.9%. That broader development stopped after the FDA put the program on hold in 2013 over findings in an animal study, and the developer then focused on resistant infections. Whether pritelivir will ever be tested again for everyday herpes is not known.

Other drugs in the same class are being developed for recurrent genital herpes in people with healthy immune systems. The furthest along is GS-1179 (formerly ABI-1179), a once-weekly helicase-primase inhibitor that Gilead licensed from Assembly Biosciences. In an early Phase 1b study, it cut HSV-2 viral shedding by 98% compared with placebo, and a Phase 2 study is expected to start by the end of 2026. A sister compound, ABI-5366, showed similar early results, but Assembly reported in August 2026 that Gilead does not plan to develop it further for now. Early results do not always hold up in larger trials, but herpes research is more active than it has been in a long time. Our herpes cure research tracker follows every program and its latest status.

Is This a Cure?

No. Pritelivir treats active herpes sores. It does not remove the virus that stays dormant in nerve cells. As of 2026 there is no cure for HSV, and the World Health Organization notes that today's antivirals reduce symptoms but cannot cure the infection.

Be careful with headlines and social media posts that call any new drug a herpes cure. Scammers use news like this to sell fake cures, herbal remedies and supplements. If someone offers you a cure, especially in a dating chat, treat it as a red flag.

Questions to Ask Your Doctor

If you are immunocompromised: Is my herpes sore healing as expected? Should my virus be tested for resistance? Could Hovilpri be an option for me once it is available? Do any of my medicines, including acid reducers, interact with it?

If your immune system is healthy: Is my current plan, episodic or suppressive, still the right one for me? What else can I do to reduce outbreaks, or the risk of passing HSV to a partner?

The Bottom Line

Hovilpri is real progress, and it is good news for the people with weakened immune systems who need it most. For everyone else with HSV, it is a hopeful sign that herpes research is moving again, not a reason to change what already works.

And you do not have to wait for the next breakthrough to have a full life, including a dating life. Herpes is common, manageable and, with today's treatments, very livable.